扩大检测并给予药物治疗是终止艾滋病流行的基础
随着社会发展和艾滋病综合防治工作不断推进,我国艾滋病疫情流行模式已经发生明显改变,经性接触感染HIV已经成为当前最主要的传播途径,不仅对疫情流行造成直接影响,而且决定着将来的疫情发展趋势。导致流行模式转变的原因包括:首先,我国是全球人口第一大国,改革开放以来,随着社会经济发展水平和人民物质生活水平逐步提高,人群期望寿命显著增加,使得有性行为活动的人群规模数量明显增多,容易受到性传播性疾病的侵袭;其次,在全球化和城镇化的进程不断加快的背景下,不同地区之间发展不平衡的现象更加凸显,存在着较大的东西南北和城乡的差距,伴随着基础设施网络不断完善,地区之间交通往来变得更加便捷,进一步加剧和促进了人口流动,大大增加了人与人之间接触交往的机会,由此也引发相关问题的产生,艾滋病感染呈缓慢上升就显示出这个问题;第三,当前,我国正处于百年之未有大变局的转型时期,社会、政治、经济、文化等方方面面正在经历各种各样的碰撞和融合,不可避免地对传统的道德观和价值观产生相应的影响,对婚前和婚外性行为保持相对开放和包容的态度,从而促进行为的发生;第四,互联网的普及在很大程度上改变了人与人之间的交友方式,由于其操作简单方便,且具有较好的隐蔽性,使得通过网络交友方式认识性伴并发生性行为的情况日益增多,尤其是在低年龄组人群中,新型毒品滥用使得毒和性交织问题持续存在,增加HIV经性接触途径感染的风险;最后,随着时间的发展,各类高危人群的取代是不可避免的,进而对综合干预效果产生影响。因此,这就突显了宣传教育和预防干预的重要性。第一,对性接触途径感染者来说,不论是异性还是同性的性接触,使用安全套是进行安全性行为的保证;第二,而对于静脉吸毒者来说,不共用注射器就能阻止HIV-1的传播;第三,请有高危行为的人们主动接受检测,自检或VCT都是知晓自身感染状况的重要方式,也是2020年底我国实现2030年终止艾滋病流行美好愿景中第一阶段90%的重要目标。“十三五”期间,我国不断扩大HIV抗体检测覆盖面,每年检测数量从2016年的1.69亿人次上升至2019年的2.77亿人次,检测人数约上升了39.0%。在我国新疆地区,2016年以来,每年接受HIV抗体检测的数量逐年增多,其人群检测比例从2016年的30.8%上升至2019年的67.0%,与此同时,每年新报告的HIV/AIDS病例数却呈逐年下降趋势,表明接受HIV抗体检测,不仅可以在疾病早期最大限度发现潜在的感染者,降低病死率,提高生存质量,而且还可以有效地减少和降低疾病的传播;第四,感染了HIV-1不等于绝症,抗逆转录病毒治疗可以有效抑制患者体内HIV复制繁殖,重建机体免疫系统功能,从而显著降低艾滋病病毒感染者/艾滋病病人的病死率。2010年以来,由于抗病毒治疗的实施,全球艾滋病相关死亡病例减少了约1210万,2019年,全球因艾滋病相关疾病导致的死亡也下降了39%。除此之外,抗病毒治疗在母婴阻断和单阳家庭预防的成功实践,也充分表明其不仅可以在延缓病情,减少死亡发生发挥重要作用,而且还可以通过规范治疗后降低患者体内的病毒载量,进而减少和消除进一步传播扩散的风险,从而达到减少HIV新发感染,使得“TasP(治疗即预防)”和“U(不能检测到的)=U(不会传播的)”已经成为当前重要防治策略在全球范围内加以推广。
(陈 亮 颜苹苹 严延生)
参考文献
[1]DeVita VT,Hellman S,Rosenberg SA,et al.AIDS(Etiology,Diagnosis,Treatment and Prevention[M].Fourth Edition.Philadelphia:Lippincott-Raven,1997.
[2]Shatp PM,Robertson DL,Gao F,et al.Origin and diversity of human immunodeficiency virus[J].AIDS,1994,1X:S27-42.
[3]Keele BF,Van Heuverswyn F,Li YY,et al.Chimpanzee Reservoirs of Pandemic and Nonpandemic HIV-1[J].Science,2006,313(5786):523-526.
[4]Aikaterini A,Yujie L,Brian W.Cellular Reservoirs of HIV-1 and their Role in Viral Persistence[J].Curr HIV Res,2008,6(5):388-400.
[5]Watts JM,Dang KK,Gorelick RJ,et al.Architecture and secondary structure of an entire HIV-1 RNA genome[J].Nature,2009,460(7256):711-716.
[6]CDC.U.S.Public health service guidelines for testing and counseling blood and plasma donors for human immunodeficiency virus type 1 antigen[J].MMWR,1996,45( RR-2) :1-9.
[7]Christopher M,Coleman ,Li WU.HIV interactions with monocytes and dendritic cells:viral latency and reservoirs[J].Retrovirology ,2009,6:51.
[8]Woodman Z,Williamson C.HIV molecular epidemiology:transmission and adaptation to human populations[J].Curr Opin HIV AIDS,2009,4( 4) :247-252.
[9]Nabel GJ.Challenges and opportunities for development of an AIDS vaccine[J].Nature ,2001,410:1002-1007.
[10]Pomerantz RJ,Zhang H.Residual HIV-1 persistence during suppressive HAART[J].Curr Clin Top Infect Dis,2001,21:1-30.
[11]DE CLERCQ E.Emerging anti-HIV drugs [J].Expert Opin Emerg,2005,l0( 2) :241-273.
[12]VajraguptaO,BoonchoongP,Morris GM,et a1.Active site binding modes of curcumin in HIV-1 protease and integrase[J].Bioorg Med Chem Lett,2005,5 (14) :3364-3368.
[13]Surman SL,Sealy R,Jones BG,et al.HIV-1 vaccine design:harnessing diverse lymphocytes to conquer a diverse pathogen[J].Hum Vaccin,2009 ,5( 4) :268-271.
[14]王陇德.艾滋病学[M].北京:北京出版社,2009.
[15]中国疾病预防控制中心.国家免费艾滋病抗病毒药物治疗手册[M].4版.北京:人民卫生出版社,2016.
[16]中国疾病预防控制中心.全国艾滋病检测技术规范(2015年修订版)[J].中国病毒病杂志,2016,6(6):401-427.
[17]Heger E,Schuetz A,Vasan S.HIV Vaccine Efficacy Trials:RV144 and Beyond[J].Adv Exp Med Biol,2018,1075:3-30.DOI:10.1007/978-981-13-0484-2_1.(https://www.daowen.com)
[18]文心田,于恩庶,徐建国,等.当代世界人兽共患病学[M].成都:四川科学技术出版社.2015.
[19]Granich R,Williams B,Montaner J,Zuniga JM.90-90-90 and ending AIDS:necessary and feasible.Lancet.2017;390:341–3.http://dx.doi.org/10.1016/S0140-6736(17)31872-X.
[20]Fauci AS,Marston HD.Ending the HIV-AIDS pandemic—follow the science.N Engl J Med.2015;373:2197–9.http://dx.doi.org/10.1056/NEJMp1502020
[21]Marcus JL,Chao CR,Leyden WA,et al.Narrowing the gap in life expectancy between HIV-infected and HIV-uninfected individuals with access to care[J].J Acquir Immune Defic Syndr,2016,73:39–46.
[22]UNAIDS.The scales have tipped—UNAIDS announces 19.5 million people on lifesaving treatment and AIDS-related deaths halved since 2005 [EB/OL]( 2017-07-20 ) [2020-03-01].http://www.unaids.org/en/resources/presscentre/pressreleaseandstatementarchive/2017/july/20170720_PR_Global_AIDS_Update_2017
[23]Cohen MS,Chen YQ,McCauley M,et al.HPTN 052 Study Team.Antiretroviral therapy for the prevention of HIV-1 transmission.N Engl J Med.2016;375:830–9.http://dx.doi.org/10.1056/NEJMoa1600693
[24]Rodger AJ,Cambiano V,Bruun T,et al.PARTNER Study Group.Sexual activity without condoms and risk of HIV transmission in serodifferent couples when the HIV-positive partner is using suppressive antiretroviral therapy[J].JAMA,2016,316:171–81.DOI:10.1001/jama.2016.5148
[25]Jacobson JM,Flexner CW.Universal antiretroviral regimens:thinking beyond one-pillonce-a-day[J].Curr Opin HIV AIDS,2017,12:343-350.DOI:10.1097COH.0000000000000374
[26]UNAIDS.Fast-Track.Ending the AIDS epidemic by 2030 [EB/OL]( 2014-11-18)[2020-03-01].http://www.unaids.org/en/resources/documents/2014/JC2686_WAD2014report
[27]Fauci AS.An HIV vaccine is essential for ending the HIV/AIDS pandemic[J].JAMA,2017,318:1535–1536.DOI:/10.1001/jama.2017.13505
[28]UNAIDS.UNAIDS stories-.90-90-90 an ambitious treatment target to help end the AIDS epidemic[EB/OL].[2020-03-01].https://www.unaids.org/sites/default/files/media_asset/90-90-90_en.pdf 283.
[29]Kouyos RD,Rusert P,Kadelka C,et al.Tracing HIV-1 strains that imprint broadly neutralizing antibody responses[J].Nature,2018,561:406–410.
[30]Marcus JL,Chao CR,Leyden WA,et al.Narrowing the gap in life expectancy between HIV-infected and HIV-uninfected individuals with access to care[J].J Acquir Immune Defic Syndr,2016,73 (1):39-46.DOI:10.1097/QAI.000000000000/014.
[31]UNAIDS.Global HIV & AIDS Statistics — 2020 Fact Sheet.[EB/OL][2020-03-01].https://www.unaids.org/en/resources/fact-sheet
[32]Rosenbloom DIS,Hill AL,Laskey SB,et al.Re-evaluating evolution in the HIV reservoir[J].Nature,2017,551(7681):E6-E9.
[33]Lorenzo-Redondo R,Fryer HR,Bedford T,et al.Persistent HIV-1 replication maintains the tissue reservoir during therapy[J].Nature,2016,530(7588):51-56.
[34]Jiao YM,Chen GL,Zhu WJ,et al.Higher viral load and genetic diversity of HIV-1 in seminal compartments than in blood of seven Chinese men who have sex with men and have early HIV-1 infection[J].Microbiol Immunol,2017,61(6):239-246.
[35]Cohen YZ,Lorenzi JCC,Krassnig L,et al.Relationship between latent and rebound viruses in a clinical trial of anti-HIV-1 antibody 3BNC117[J].J Exp Med,2018,215( 9) :2311-2324.
[36]陈曦.艾滋病抗病毒治疗时代扩大检测的策略[J].中华预防医学杂,2018,12:1210-1214.
[37]Plantier JC,LEOZ M,Dickerson JE,et al.A new human immuodeficiency virus derived from gorillas[J].Nat Med,2009,15:871-872.